**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 66060

**Manuscript Type:** MINIREVIEWS

**Hemodynamic management in brain dead donors**

Lazzeri C *et al*. Hemodynamic management in DBD

Chiara Lazzeri, Manuela Bonizzoli, Cristiana Guetti, Giorgio Enzo Fulceri, Adriano Peris

**Chiara Lazzeri, Manuela Bonizzoli, Cristiana Guetti, Giorgio Enzo Fulceri, Adriano Peris,** Intensive Care Unit and Regional ECMO Referral Centre, Azienda Ospedaliero Universitaria Careggi, Florence 50134, Italy

**Author contributions:** Lazzeri C, Peris A, Bonizzoli M performed the majority of the writing, prepared the tables; Guetti C performed data accusation and writing; Fulceri GE provided the input in writing the paper.

**Corresponding author: Chiara Lazzeri, MD, Senior Researcher,** Intensive Care Unit and Regional ECMO Referral Centre, Azienda Ospedaliero Universitaria Careggi, Viale Morgagni 85, Florenze 50134, Italy. lazzeri.ch@gmail.com

**Received:** March 20, 2021

**Revised:** July 22, 2021

**Accepted:** September 10, 2021

**Published online:**

**Abstract**

Donor management is the key in the complex donation process, since up to 20% of organs of brain death donors (DBD) are lost due to hemodynamic instability. This challenge is made more difficult due to the lack of strong recommendations on therapies for hemodynamic management in DBDs and more importantly to the epidemiologic changes in these donors who are becoming older and with more comorbidities (marginal donors). In the present manuscript we aimed at summarizing the available evidence on therapeutic strategies for hemodynamic management (focusing on vasoactive drugs) and monitoring (therapeutic goals). Evidence on management in elderly DBDs is also summarized. Donor management continues critical care but with different and specific therapeutic goals since the number of donor goals met is related to the number of organs retrieved and transplanted. Careful monitoring of selected parameters (possibly including serial echocardiography) is the clinical tool able to guarantee the achievement and maintaining of therapeutic goals. Despide worldwide differences, norepinephrine is the vasoactive of choice in most countries but, whenever higher doses (> 0.2 mcg/kg/min) are needed, a second vasoactive drug (vasopressin) is advisable. Hormonal therapy (desmopressin, corticosteroid and thyroid hormone) are suggested in all DBDs independently of hemodynamic instability. In the single patient, therapeutic regimen (imprimis vasoactive drugs) should be chosen also according to the potential organs retrievable (*i.e.* heart *vs* liver and kidneys).

**Key Words:** Brain-dead donors; Hemodynamic; Management; Vasoactive drugs; Hormanal therapy; Echocardiography

Lazzeri C, Bonizzoli M, Guetti C, Fulceri GE, Peris A. Hemodynamic management in brain dead donors. *World J Transplant* 2021; In press

**Core Tip:** Donor management continues critical care but with different and specific therapeutic goals since the number of donor goals met is related to the number of organs retrieved and transplanted. Careful monitoring of selected parameters (possibly including serial echocardiography) is the clinical tool able to guarantee the achievement and maintaining of therapeutic goals. In the single patient, therapeutic regimen (imprimis vasoactive drugs) should be chosen also according to the potential organs retrievable (*i.e.* heart *vs* liver and kidneys).

**INTRODUCTION**

The number of patients on waiting list for transplant is increasing with a still high mortality rate and greater efforts should be made to maximize the organ pool and optimize organ quality from donors.

Donor management is key in the complex donation process, since up to 20% of organs of brain death donors (DBD) are lost due to hemodynamic instability[1-3]. This challenge is made more difficult due to the lack of strong recommendations on therapies for hemodynamic management in DBDs and more importantly to the epidemiologic changes in these donors who are becoming older and with more comorbidities (marginal donors)[4].

In the present manuscript we aimed at summarizing the available evidence on therapeutic strategies for hemodynamic management (focusing on vasoactive drugs) and monitoring (therapeutic goals). Evidence on management in elderly DBDs is also summarized.

A “PubMed” search was made using the words “Brain death donors and hemodynamics and adults”. Only articles in English language were included referring to adults, while case reports and investigations on children were not comprised.

**Rationale**

A consistent number of donors are unfortunately lost because not properly treated[5],underscoring the pivotal role of active critical care to mitigate the imbalance between demand and supply of organs for transplantation. Though complex, intensive care management of potential donors, by the achievement of therapeutic goals, was associated with a 2-fold increase in transplanted organs[6]. This concept is further proved by the analysis of outcomes of two renal recipients from the same donor and of failure of multiorgan transplantation from the same donor[7,8].

**Therapeutic goals**

In essence, donor management continues critical care but with different and specific therapeutic goals.

A checklist of nine therapeutic donor goals (DG) was proposed by eight organ procurement organization in United Network for Organ Sharing region[9]. The number of met DGs was reported to progressively increase from the time to diagnosis of brain death to organ recovery (from 15% to 38%). DG met at the time of consent were related to the number of transplanted organs, since if more four DGs were met at the time of cosent, an odd ratio of 2.03 was reported for at least four organs transplanted. Moreover, if more than 7 DGs were met after consent a reduced need of dialysis in the first week after transplant was observed[10].

A key question was whether the time of donor treatment could influence the number and quality of transplanted organs. According the results of prospective studies, a longer period of donor treatment was associated with a higher number of organs transplanted in the lack of differences in the number of DGs achieved. This phenomenon was more evident for heart and lung transplantation probably thanks to an efficacious treatment of potential reversible cardiac diseases such as stress cardiomyopathy[11-14]. In the United States longer periods of management are common and a “relax and repair approach” was proposed in opposition to a “rush and retrieve” one (that is, in presence of donor stability a risk of deterioration can be avoided since little can be achieved).

Due to the frequently encountered hemodynamic instability, historically DG were developed in order to maintain physiologic homeostasis. An early series of goals, the so-called series of 100: Systolic pressure > 100 mmHg, urine output > 100 mL/h, partial pressure of O2 (PaO2) > 100 mg and hemoglobin concentration > 100 mg/dL[15].

In the subsequent years, guidelines for donor treatments and other goals were introduced, even if there is great worldwide variations in management strategies[16,17].

DG is shown in Table 1. Despite disparities in guidelines[18], these goals are based on clinical practice and their clinical significance comes from serial measurements during donor management and subsequent adaptation of therapies. Each parameter should be clinically and critically interpreted in the single patient. For instance, high values of central venous pressure can be observed in patients with chronic cor pulmonare and moderate tricuspid regurgitation, independently of the volemic status; in this clinical condition, dynamic changes of central venous pressure should be considered.

**Hemodynamic management**

Hemodynamic management is considered really a challenge due to the quite high frequency of donor instability. The severity of circulatory changes have been related to the speed of brain death. More severe hemodynamic alterations were described when brain death develops in a shorter time[19].

Two are the main physiopathologic steps in hemodynamic derangements: (1) The sympathetic storm (following the increase in intracranial cerebral pressure and progressive brainstem ischemia) causes compensatory arterial hypertension and raised systemic vascular resistance, associated with central redistribution of blood volume. It follows an increased after load and eventually visceral ischemia; and (2) Peripheral vasodilation due to the abrupt loss of sympathetic tone. Endocrine changes may worsen this phenomenon mainly by volume depletion.

In these patients, as brain death develops, treatment for hemodynamic imbalance shifts from preventing injuries from increased sympathetic tone (ischemic injury) to counterbalancing systemic injuries due to magnified vasodilation (ineluctably leading to reperfusion injury).

Despite no major studies specifically addressed which monitoring tools should be applied in DBDs, the following monitoring sets could be suggested according to clinical practice: (1) Invasive arterial pressure (mean arteria pressure ≥ 65 mmHg); (2) Urine output (≥ 1 mL/kg/h); (3) Central venous pressure (8-10 cm H2O); (4) Lactate values; (5) Mixed venous oxygen saturation; and (6) Echocardiography (mainly to assess left and right ventricular functions and to exclude previous or newly developed cardiac alterations).

Echocardiography has emerged as a clinical useful tool in intensive care unit (ICU) every day clinical practice. In patients with severe neurologic injury, serial echocardiographic assessments give the opportunity to provide useful information to tailor hemodynamic regimen in the single patient and, moreover, to identify potential reversible clinical conditions (*i.e.* stress cardiomyopathy) whose early treatment could lead to an increased number of trapiantable hearts and, even in the older donor, to an hemodynamic stabilization.

The reversibility in left ventricle (LV) dysfunction in patients with severe brain injury has been described as “neurogenic stunned myocardium”[20], mainly on the basis of data obtained in experimental models[21-23] and on a few investigations performed in humans[24,25]. Several papers documented that aggressive treatment in BD donors was associated with improvement in myocardial function and with an increased number of transplanted hearts, previously considered not suitable for transplantation[26-28]. In 49 patients with severe brain injury (potential heart donors), our group observed that echocardiography performed after ICU admission led to the identification of LV abnormalities potentially reversible after tempestive aggressive treatment. Indeed, in our series, two patients were considered eligible for heart donation, resulting in 20% increase in donor retrieval rate[14].

In a large analysis[12] (United Network of Organ Sharing database, 2007-2015) of 472 donor hearts with left ventricular ejection fraction < 40%, on initial transthoracic echocardiography which recovered during donor treatment, it was reported successful transplantation of these hearts with no increase in adverse outcomes (cardiac allograph outcome, primary graft failure) when compared to hearts which did not experienced LV dysfunction. Similarly, in Sweden (dataset 2006-2016) 45 hearts (of 338 donor hearts) with LV dysfunction were transplanted, and after transplantation LV ejection fraction normalized in all recipients. Short-term outcomes or the composite end point of death or retransplantation over time were comparable between recipients of donor hearts with *vs* without LV dysfunction[29].

All these findings underscore the utility of serial echocardiographic examinations in severe neurologic acute injury for the identification of potential reversible cardiac conditions, eligible for early aggressive treatments. Thanks to this clinical and methodologic approach, some hearts considered not suitable for transplantation could be successfully transplanted.

**Vasoactive drugs**

***Dopamine***

A retrospective-case control study, performed in Germany in 1999, reported that dopamine use in DBDs resulted in improved graft survival after kidney transplantation[30-34]. These results were confirmed in a large cohort study of 2704 DBD kidney grafts (Eurotransplant Registry)[31] and in 254 recipients of kidney transplantation[33]. The beneficial effects of dopamine on kidney grafts were related not only to the hemodynamic effects of dopamine but mainly to its ability to scavance reactive oxygen species (by preventing the depletion of glutathione)[34]. In a randomized controlled trial including 264 DBDs, the use of low dose dopamine (4 mcg/kg/min) was associated with a reduced requirement for dialysis in recipients of the dopamine group[35]. However, the percentage of patients also on norepinephrine was quite high both in the dopamine and in the control groups (78.4% and 85.6%, respectively).

According to the follow-up trial, an improved survival was observed only if dopamine treatment was longer that 7 h till cross clamp. In the same trial, an improved outcome of heart grafts was observed in dopamine treated patients[36].

Regarding the effects of dopamine use on the outcomes of other organs, data are more conflicting. Dopamine pretreatment has no effect on liver transplantation probably because it is rapidly degraded in hepatocytes[34]. Concerning the heart, high dose of dopamine donor treatment (> 10mcg/kg/min) showed no association with mortality in 568 heart transplants[37]. In the study by von Ziegler *et al*[38] donor pre-treatment with norepinephrine was compared with dopamine pre-treatment in heart transplants and no differences were observed in survival between the two subgroups. However, in a subset population of long term (5-year) follow-up, norepinefrine was associated with better survival.

In recent years, dopamine was eliminated from routine use in ICU due to large individual variation in dopamine clearance (with unpredictable adrenergic stimulation[34,39,40]). Regarding DBD management and based on growing evidence, dopamine use cannot be advised due to the lack of evidence of beneficial effects in the multiorgan donor and the scarce vasoconstrictor effect of dopamine at low doses. Indeed, its use has been progressively replaced by norepinephrine in most countries worldwide[18].

***Vasopressin***

Vasopressin can be used to treat both diabetes insipidus and hypotension thanks to its action on V2 renal receptors and on V1 receptors on smooth muscle cells. Due to its short half life, it should be administered by infusion with an usual dosage range of 0.5 to 2.4 units *per* hour. Higher doses may cause deleterious vasoconstritor effects in several districts (renal, splachnic, pulmonary and coronary districts[41]). In a large cohort of 10431 DBDs, donor vasopressor use was an independent predictor of a high number (≥ 4 organs) of procured organs. However, this study focuses on donor hemodynamic parameters and not on allograft outcomes[42]. To date, no data are consistent with the potential advantage of vasopressin over other vasoactive agents, even if vasopressin is the drug of choice for hypotension in DBDs in some countries such as Canada, Ireland and India[18].

***Norepinephrine***

Norepinephrine is the vasoactive drug of choice in several countries including Europe[4,18] with an increasing use in the last years, despite not univocal literature data. A beneficial effect of norepinephrine use was reported in 270 kidney recipients, since decreased rates of graft rejection and loss followed increased number of norepinephrine infusion days[43].

In regard to heart transplantation, conflicting results are reported on norepinephrine dosage and graft outcomes[44,45]. According to a survey, in potential heart donors, most heart transplant centers in United Sttaes are reluctant to accept donors under moderate dose of catecholamine[46]. High dose norepinephrine was correlated with right ventricular impairment and adverse 1-year outcome in a prospective investigation[47]. Conversely no differences in short term mortality was observed in a German Registry between different norepinephrine doses[48].

Based on this conflicting evidence, in potential heart donors we suggest to add vasopressin (continuous infusion) when a dose of norepinephrine > 0.2 mcg/kg/min is needed.

***Hormonal therapy***

The rationale for hormonal supportive therapy in BD donors comes from the physiopathology of brain death. Insulin and glucose management can be considered part of the intensive care management.

In human brain death, posterior pituitary dysfunction is commonly encountered (as documented by the frequency of diabetes insipidus), while anterior pituitary function may be only partially affected, probably thanks to the preserved pituitary blood flow. Thus, the hormones usually affected are antidiuretic hormone (ADH), thyroid hormones and cortisol[41].

Deficient levels of vasopressin (also known as ADH) were reported in up to the 80% of brain dead donors[49] and diabetes insipidus was described in the 77% of donors in Australia[50]. Low free T3 are frequently encountered in human donors, while variable concentrations of TSH and T4 are reported. The changes in thyroid hormones in brain death seem to resemble the euthyroid sick syndrome, commonly seen in critically ill patients[22,51,52].

Growing evidence does support the use of hormonal replacement therapy in DB donors, independently of hemodynamic instability[52-55]. In 1995, in an United Kingdom center, most donors were initiated on hormone replacement therapy by infusion, which led to the conversion of many of donors initially considered to be unacceptable, based on hemodynamic parameters, to acceptable donors[56]. In a cohort of 47 DBDs (2006 to 2011), hormonal replacement therapy initiated in the lack of hemodynamic instability was independently associated with highly-yield (≥ 4 organs) procurement[29]. A shorter duration of norepinephrine administration was also observed in this subgroup.

Treatment of diabetes insipidus is essential for donor stability. If untreated, diabetes insipidus causes hypovolemia, and marked hypernatremia which may be detrimental to organ outcome, especially for liver and kidney graft outcomes[57,58].Diabetes insipidus should be suspected in presence of polyuria of ≥ 3 mL/kg/h and/or rising serum sodium levels) and the synthetic vasopressin analogue 1-deamino-8-D-arginine vasopressin (DDVAP) should be used. It selectively acts on V2 renal receptors and it does not have vasoconstrictor activity. DDVAP can be given as an intravenous bolus of between 2 and 6 mcg since it has a much longer half-life than vasopressin. At higher doses (0.3 mcg/kg) DDVAP exerts procoagulant effects (Table 2).

Administration of thyroid hormone has been highly suggested in guidelines and reviews[54,59-62]. According to animal and humans studies[63,64], replacement of thyroid hormone is able to restore and reactivate mitochondrial energy metabolism. At the cardiac level, it induces an increase alpha heavy chain formation and a decrease in beta heavy chain formation, and an improvement in calcium handling, up regulation of beta adrenergic receptors, leading to a positive inotropic effect[65].

In an interesting review[66], it was reported that all retrospective analyses documented that thyroid hormone administration was beneficial. Recent evidence[64,67] does support the notion that thyroid administration in brain death is associated with an increased number of organ transplanted and improved survival of heart recipients. A 5-year recipient survival improvement was documented in heart recipients when thyroid hormone had been administered[68].

T3 may be initiated with a 4 mg intravenous bolus followed by infusion of 3 mg *per* hour alternatively, T4 may be given initially with a 20 mg intravenous bolus followed by infusion of 10 mg *per* hour.

The rationale for the administration of cortisols, the third component of hormal replacement therapy, relies on replacing steroid in pituitary-adrenal dysfunction, on supplementing steroid because of a “functional” or “relative” adrenal insufficiency, and on the immunomodulatory and anti-inflammatory beneficial effects of steroids.

Evidence supports this notion. Weaning of norepinephrine was more frequent in the 80 BD donors who received steroids than the 128 ones who did not, although no benefit was observed in primary functional recovery of transplanted grafts[69]. Recipients of donor livers who had received steroids showed less ischemia-reperfusion injury and acute rejection[70]. Low-dose of steroids is preferred since high dose did not show differences in number of retrieved and transplanted organs[52,71-73].

Different regimens of steroids were described with no documented benefit of one over the other[18]. Based on our experience, we suggest the use of hydrocortisone 100 mg bolus followed by 200 mg/d (continuous infusion).

**Age and brain dead donors**

The characteristics of the pool of BD donors have deeply changed over the past years especially in developed Western countries. While DBDs were once largely young and declared dead due to traumatic brain injury, they are now older, with more comorbidities and declared dead due to cerebrovascular injury[74,75]. This phenomenon was confirmed in Italy (Tuscany Region) in a cohort of 1286 potential heart donor (aged ≤ 60) over a 15-year period in whom we observed an age increase and a change in brain dead causes (mainly a reduction in the incidence of traumatic brain injury)[4].

After BD development, the only variation observed with advancing age is lower values of diastolic blood pressure, which is most likely related to arterial changes due to aging[76]. Diastolic blood pressure is known to increase up to the age of about 50 years due to the rise in arteriolar resistance, but, later in life, the large artery stiffening contributes a wider pulse pressure including a decreased diastolic blood pressure. In the BD donor, this phenomenon may affect perfusion pressure, highlighting potential difficulties in hemodynamic management in older donors, and it may be worsened by the age-related reduction in β-receptor function[77]. In 92 consecutive DBDs[78], advancing age was associated with a more pronounced vasodilatation (lower values of diastolic blood pressure) probably due to age-related reduction in arterial stiffness and beta-receptor function (conditioning a reduced response to endogenous and/or exogenous norepinephrine stimulation).

Older DBDs usually donate liver and/or kidney. Though the monitoring set and hemodynamic goals do not differ from younger DBDs, clinical peculiarities in management may apply to older DBDs. Due to the coexistence of atherosclerotic age-related disease (involving also small vessels), the lowest dosage of vasoactive drugs should be used, able to achieve and grantee the best perfusion of abdominal organs, as mainly indicated by urine output and dynamic lactate values. Though fluid restriction is not required, close monitoring of sodium is needed in potential liver donors. In older DBDs, the possibility of *ex vivo* perfusion should be considered, mainly in presence of comorbidities (in primis diabetes and hypertension) and not optimal indices of organ perfusion (*i.e.* Transaminases values).

**Timing for an optimal management**

The main target of “an early management” is the achievement of good systemic perfusion since ICU admission in a patient with severe neurologic injury, despite his/her potential non favorable outcome. According to our experience, three steps can be identified for an efficacious treatment. The first one starts with ICU admission of a patient with severe neurologic injury and it is strictly part of critical care, consisting of hemodynamic, metabolic and infectious monitoring. In this phase, an echocardiographic assessment allows the detection of previous (eventually unknown) heart disease as well as new-onset cardiac conditions, such as stress cardiomyopathy, which deserve targeted therapies. Dosages of vasoactive drugs should be tailored in order to avoid excessive organs' vasoconstriction, possibly by means of close monitoring of hemodynamic targets (in primis central venous pressure and lactate values). The second step is represented by treatments during brain death development and it mainly consists in the management of hemodynamic and metabolic deragements. Finally the third step, that is properly “DBD management”, since brain death diagnosis to the operating theatre.

**Key messages**

Intensive care management should begin on ICU admission of a patient with severe acute neurologic injury at risk of developing brain death. With the aim to reach optimal systemic organ perfusion and identify all reversible clinical conditions (*i.e.* Stress cardiomyopathy) elegible for efficaceous treatment.

In the single patient, therapeutic regimen (imprimis vasoactive drugs) should be chosen also according to the potential organs retrievable (*i.e.* heart *vs* liver and kidneys).

Donor age may affect management due to peculiarities of brain death in older donors.

The utility of serial echocardiographic examinations in severe neurologic acute injury for the identification of potential reversible cardiac conditions, eligible for early aggressive treatments. Thanks to this clinical and methodological approach, some hearts considered not suitable for transplantation could be successfully transplanted.

Hormal replacement therapy should be initiated in DBDs independently of hemodynamic instability.

**CONCLUSION**

Donor management continues critical care but with different and specific therapeutic goals since the number of DG met is related to the number of organs retrieved and transplanted. Careful monitoring of selected parameters (possibly including serial echocardiography) is the clinical tool able to guarantee the achievement and maintaining of therapeutic goals. In the single patient, therapeutic regimen (imprimis vasoactive drugs) should be chosen also according to the potential organs retrievable (*i.e.* heart *vs* liver and kidneys).

**REFERENCES**

1 **Martin-Loeches I**, Sandiumenge A, Charpentier J, Kellum JA, Gaffney AM, Procaccio F, Westphal GA. Management of donation after brain death (DBD) in the ICU: the potential donor is identified, what's next? *Intensive Care Med* 2019; **45**: 322-330 [PMID: 30820584 DOI: 10.1007/s00134-019-05574-5]

2 **Patel MS**, De La Cruz S, Sally MB, Groat T, Malinoski DJ. Active Donor Management During the Hospital Phase of Care Is Associated with More Organs Transplanted per Donor. *J Am Coll Surg* 2017; **225**: 525-531 [PMID: 28739153 DOI: 10.1016/j.jamcollsurg.2017.06.014]

3 **Patel MS**, Zatarain J, De La Cruz S, Sally MB, Ewing T, Crutchfield M, Enestvedt CK, Malinoski DJ. The impact of meeting donor management goals on the number of organs transplanted per expanded criteria donor: a prospective study from the UNOS Region 5 Donor Management Goals Workgroup. *JAMA Surg* 2014; **149**: 969-975 [PMID: 25054379 DOI: 10.1001/jamasurg.2014.967]

4 **Peris A**, Lazzeri C, D'Antonio L, Bombardi M, Bonizzoli M, Guetti C, Maccherini M, Migliaccio ML. Epidemiological changes in potential heart donors after brain death: a retrospective 15 year cohort study. *Intern Emerg Med* 2019; **14**: 371-375 [PMID: 29943077 DOI: 10.1007/s11739-018-1897-8]

5 **Salim A**, Velmahos GC, Brown C, Belzberg H, Demetriades D. Aggressive organ donor management significantly increases the number of organs available for transplantation. *J Trauma* 2005; **58**: 991-994 [PMID: 15920414 DOI: 10.1097/01.ta.0000168708.78049.32]

6 **McKeown DW**, Ball J. Treating the donor. *Curr Opin Organ Transplant* 2014; **19**: 85-91 [PMID: 24553498 DOI: 10.1097/MOT.0000000000000059]

7 **Robert R**, Guilhot J, Pinsard M, Longeard PL, Jacob JP, Gissot V, Hauet T, Seguin F. A pair analysis of the delayed graft function in kidney recipient: the critical role of the donor. *J Crit Care* 2010; **25**: 582-590 [PMID: 20381298 DOI: 10.1016/j.jcrc.2010.02.011]

8 **Oto T**, Excell L, Griffiths AP, Levvey BJ, Bailey M, Marasco S, Macdonald P, Snell GI. Association between primary graft dysfunction among lung, kidney and heart recipients from the same multiorgan donor. *Am J Transplant* 2008; **8**: 2132-2139 [PMID: 18727699 DOI: 10.1111/j.1600-6143.2008.02357.x]

9 **Malinoski DJ**, Patel MS, Daly MC, Oley-Graybill C, Salim A; UNOS Region 5 DMG workgroup. The impact of meeting donor management goals on the number of organs transplanted per donor: results from the United Network for Organ Sharing Region 5 prospective donor management goals study. *Crit Care Med* 2012; **40**: 2773-2780 [PMID: 22846779 DOI: 10.1097/CCM.0b013e31825b252a]

10 **Malinoski DJ**, Patel MS, Ahmed O, Daly MC, Mooney S, Graybill CO, Foster CE, Salim A; United Network for Organ Sharing (UNOS) Region 5 Donor Management Goals (DMG) Workgroup. The impact of meeting donor management goals on the development of delayed graft function in kidney transplant recipients. *Am J Transplant* 2013; **13**: 993-1000 [PMID: 23406284 DOI: 10.1111/ajt.12090]

11 **Berman M**, Ali A, Ashley E, Freed D, Clarke K, Tsui S, Parameshwar J, Large S. Is stress cardiomyopathy the underlying cause of ventricular dysfunction associated with brain death? *J Heart Lung Transplant* 2010; **29**: 957-965 [PMID: 20627624 DOI: 10.1016/j.healun.2010.04.008]

12 **Casartelli M**, Bombardini T, Simion D, Gaspari MG, Procaccio F. Wait, treat and see: echocardiographic monitoring of brain-dead potential donors with stunned heart. *Cardiovasc Ultrasound* 2012; **10**: 25 [PMID: 22721412 DOI: 10.1186/1476-7120-10-25]

13 **Munshi L**, Keshavjee S, Cypel M. Donor management and lung preservation for lung transplantation. *Lancet Respir Med* 2013; **1**: 318-328 [PMID: 24429157 DOI: 10.1016/S2213-2600(12)70064-4]

14 **Lazzeri C**, Guetti C, Migliaccio ML, Ciapetti M, Peris A. The utility of serial echocardiograms for organ procurement in brain death. *Clin Transplant* 2017; **31** [PMID: 28836706 DOI: 10.1111/ctr.13094]

15 **Gelb AW**, Robertson KM. Anaesthetic management of the brain dead for organ donation. *Can J Anaesth* 1990; **37**: 806-812 [PMID: 2225301 DOI: 10.1007/BF03006543]

16 **Selck FW**, Deb P, Grossman EB. Deceased organ donor characteristics and clinical interventions associated with organ yield. *Am J Transplant* 2008; **8**: 965-974 [PMID: 18341685 DOI: 10.1111/j.1600-6143.2008.02205.x]

17 **Franklin GA**, Santos AP, Smith JW, Galbraith S, Harbrecht BG, Garrison RN. Optimization of donor management goals yields increased organ use. *Am Surg* 2010; **76**: 587-594 [PMID: 20583513 DOI: 10.1177/000313481007600621]

18 **Turner AJ**, Hick PE. Inhibition of aldehyde reductase by acidic metabolites of the biogenic amines. *Biochem Pharmacol* 1975; **24**: 1731-1733 [PMID: 16 DOI: 10.1016/0006-2952(75)90016-7]

19 **Frenette AJ**, Williamson D, Weiss MJ, Rochwerg B, Ball I, Brindamour D, Serri K, D'Aragon F, Meade MO, Charbonney E. Worldwide management of donors after neurological death: a systematic review and narrative synthesis of guidelines. *Can J Anaesth* 2020; **67**: 1839-1857 [PMID: 32949008 DOI: 10.1007/s12630-020-01815-0]

20 **McKeown DW**, Bonser RS, Kellum JA. Management of the heartbeating brain-dead organ donor. *Br J Anaesth* 2012; **108 Suppl 1**: i96-107 [PMID: 22194439 DOI: 10.1093/bja/aer351]

21 **Kenigsberg BB**, Barnett CF, Mai JC, Chang JJ. Neurogenic Stunned Myocardium in Severe Neurological Injury. *Curr Neurol Neurosci Rep* 2019; **19**: 90 [PMID: 31720870 DOI: 10.1007/s11910-019-0999-7]

22 **Pandalai PK**, McLean KM, Bulcao CF, Duffy JY, D'Souza KM, Merrill WH, Pearl JM, Akhter SA. Acute beta-blockade prevents myocardial beta-adrenergic receptor desensitization and preserves early ventricular function after brain death. *J Thorac Cardiovasc Surg* 2008; **135**: 792-798 [PMID: 18374758 DOI: 10.1016/j.jtcvs.2007.09.038]

23 **Shivalkar B**, Van Loon J, Wieland W, Tjandra-Maga TB, Borgers M, Plets C, Flameng W. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. *Circulation* 1993; **87**: 230-239 [PMID: 8419012 DOI: 10.1161/01.cir.87.1.230]

24 **Novitzky D**, Wicomb WN, Cooper DK, Rose AG, Reichart B. Prevention of myocardial injury during brain death by total cardiac sympathectomy in the Chacma baboon. *Ann Thorac Surg* 1986; **41**: 520-524 [PMID: 3707246 DOI: 10.1016/s0003-4975(10)63032-9]

25 **Guglin M**. How to increase the utilization of donor hearts? *Heart Fail Rev* 2015; **20**: 95-105 [PMID: 24858482 DOI: 10.1007/s10741-014-9434-y]

26 **Madias JE**. Donor hearts, hearts of resuscitated cardiac arrest victims, hearts of patients with neurogenic stress cardiomyopathy, and hearts of patients with Takotsubo syndrome: any commonalities? *Int J Cardiol* 2015; **199**: 33 [PMID: 26173172 DOI: 10.1016/j.ijcard.2015.06.184]

27 **Wheeldon DR**, Potter CD, Oduro A, Wallwork J, Large SR. Transforming the "unacceptable" donor: outcomes from the adoption of a standardized donor management technique. *J Heart Lung Transplant* 1995; **14**: 734-742 [PMID: 7578183]

28 **Zaroff JG**, Rordorf GA, Ogilvy CS, Picard MH. Regional patterns of left ventricular systolic dysfunction after subarachnoid hemorrhage: evidence for neurally mediated cardiac injury. *J Am Soc Echocardiogr* 2000; **13**: 774-779 [PMID: 10936822 DOI: 10.1067/mje.2000.105763]

29 **Madan S**, Saeed O, Vlismas P, Katsa I, Patel SR, Shin JJ, Jakobleff WA, Goldstein DJ, Sims DB, Jorde UP. Outcomes After Transplantation of Donor Hearts With Improving Left Ventricular Systolic Dysfunction. *J Am Coll Cardiol* 2017; **70**: 1248-1258 [PMID: 28859788 DOI: 10.1016/j.jacc.2017.07.728]

30 **Oras J**, Doueh R, Norberg E, Redfors B, Omerovic E, Dellgren G. Left ventricular dysfunction in potential heart donors and its influence on recipient outcomes. *J Thorac Cardiovasc Surg* 2020; **159**: 1333-1341.e6 [PMID: 31427100 DOI: 10.1016/j.jtcvs.2019.06.070]

31 **Schnuelle P**, Lorenz D, Mueller A, Trede M, Van Der Woude FJ. Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation. *Kidney Int* 1999; **56**: 738-746 [PMID: 10432416 DOI: 10.1046/j.1523-1755.1999.00567.x]

32 **Schnuelle P**, Berger S, de Boer J, Persijn G, van der Woude FJ. Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. *Transplantation* 2001; **72**: 455-463 [PMID: 11502976 DOI: 10.1097/00007890-200108150-00017]

33 **Schnuelle P**, Yard BA, Braun C, Dominguez-Fernandez E, Schaub M, Birck R, Sturm J, Post S, van der Woude FJ. Impact of donor dopamine on immediate graft function after kidney transplantation. *Am J Transplant* 2004; **4**: 419-426 [PMID: 14961996 DOI: 10.1111/j.1600-6143.2004.00331.x]

34 **Shapey IM,** Muiesan P. Regional perfusion by extracorporeal membrane oxygenation of abdominal organs from donors after circulatory death: a systematic review. *Liver Transpl* 2013; **19:** 1292-303 [PMID: 24136827 DOI: 10.1002/lt.23771]

35 **Schnuelle P**, Benck U, Yard BA. Dopamine in transplantation: Written off or comeback with novel indication? *Clin Transplant* 2018; **32**: e13292 [PMID: 29790212 DOI: 10.1111/ctr.13292]

36 **Schnuelle P**, Gottmann U, Hoeger S, Boesebeck D, Lauchart W, Weiss C, Fischereder M, Jauch KW, Heemann U, Zeier M, Hugo C, Pisarski P, Krämer BK, Lopau K, Rahmel A, Benck U, Birck R, Yard BA. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. *JAMA* 2009; **302**: 1067-1075 [PMID: 19738091 DOI: 10.1001/jama.2009.1310]

37 **Benck U**, Hoeger S, Brinkkoetter PT, Gottmann U, Doenmez D, Boesebeck D, Lauchart W, Gummert J, Karck M, Lehmkuhl HB, Bittner HB, Zuckermann A, Wagner F, Schulz U, Koch A, Bigdeli AK, Bara C, Hirt S, Berchtold-Herz M, Brose S, Herold U, Boehm J, Welp H, Strecker T, Doesch A, Birck R, Krämer BK, Yard BA, Schnuelle P. Effects of donor pre-treatment with dopamine on survival after heart transplantation: a cohort study of heart transplant recipients nested in a randomized controlled multicenter trial. *J Am Coll Cardiol* 2011; **58**: 1768-1777 [PMID: 21996389 DOI: 10.1016/j.jacc.2011.05.060]

38 **von Ziegler F**, Helbig S, Kreissl N, Meiser B, Becker A, Kaczmarek I. Norepinephrine versus dopamine pretreatment of potential heart donors - impact on long-term outcome. *Ann Transplant* 2013; **18**: 320-326 [PMID: 23792536 DOI: 10.12659/AOT.883960]

39 **Smits JM**, De Pauw M, de Vries E, Rahmel A, Meiser B, Laufer G, Zuckermann A. Donor scoring system for heart transplantation and the impact on patient survival. *J Heart Lung Transplant* 2012; **31**: 387-397 [PMID: 22177692 DOI: 10.1016/j.healun.2011.11.005]

40 **Holmes CL**, Walley KR. Bad medicine: low-dose dopamine in the ICU. *Chest* 2003; **123**: 1266-1275 [PMID: 12684320 DOI: 10.1378/chest.123.4.1266]

41 **Galley HF**. Renal-dose dopamine: will the message now get through? *Lancet* 2000; **356**: 2112-2113 [PMID: 11191531 DOI: 10.1016/S0140-6736(00)03484-X]

42 **Opdam HI**. Hormonal Therapy in Organ Donors. *Crit Care Clin* 2019; **35**: 389-405 [PMID: 30784617 DOI: 10.1016/j.ccc.2018.11.013]

43 **Plurad DS**, Bricker S, Neville A, Bongard F, Putnam B. Arginine vasopressin significantly increases the rate of successful organ procurement in potential donors. *Am J Surg* 2012; **204**: 856-60; discussion 860-1 [PMID: 23116641 DOI: 10.1016/j.amjsurg.2012.05.011]

44 **Birtan D**, Arslantas MK, Altun GT, Dincer PC, Gecegormez S, Demirel A, Ayanoglu HO. Effect of Vasoactive Therapy Used for Brain-Dead Donors on Graft Survival After Kidney Transplantation. *Transplant Proc* 2018; **50**: 1289-1291 [PMID: 29735214 DOI: 10.1016/j.transproceed.2018.02.058]

45 **Segovia J**, Cosío MD, Barceló JM, Bueno MG, Pavía PG, Burgos R, Serrano-Fiz S, García-Montero C, Castedo E, Ugarte J, Alonso-Pulpón L. RADIAL: a novel primary graft failure risk score in heart transplantation. *J Heart Lung Transplant* 2011; **30**: 644-651 [PMID: 21470878 DOI: 10.1016/j.healun.2011.01.721]

46 **Angleitner P**, Kaider A, Gökler J, Moayedifar R, Osorio-Jaramillo E, Zuckermann A, Laufer G, Aliabadi-Zuckermann A. High-dose catecholamine donor support and outcomes after heart transplantation. *J Heart Lung Transplant* 2018; **37**: 596-603 [PMID: 29370971 DOI: 10.1016/j.healun.2017.12.015]

47 **Kobashigawa J**, Khush K, Colvin M, Acker M, Van Bakel A, Eisen H, Naka Y, Patel J, Baran DA, Daun T, Luu M, Olymbios M, Rogers J, Jeevanandam V, Esmailian F, Pagani FD, Lima B, Stehlik J. Report From the American Society of Transplantation Conference on Donor Heart Selection in Adult Cardiac Transplantation in the United States. *Am J Transplant* 2017; **17**: 2559-2566 [PMID: 28510318 DOI: 10.1111/ajt.14354]

48 **Fiorelli AI**, Branco JN, Dinkhuysen JJ, Oliveira Junior JL, Pereira TV, Dinardi LF, Santos MM, Dias RR, Pereira LA, Stolf NA. Risk factor analysis of late survival after heart transplantation according to donor profile: a multi-institutional retrospective study of 512 transplants. *Transplant Proc* 2012; **44**: 2469-2472 [PMID: 23026622 DOI: 10.1016/j.transproceed.2012.07.025]

49 **Kutschmann M**, Fischer-Fröhlich CL, Schmidtmann I, Bungard S, Zeissig SR, Polster F, Kirste G, Frühauf NR. The joint impact of donor and recipient parameters on the outcome of heart transplantation in Germany after graft allocation. *Transpl Int* 2014; **27**: 152-161 [PMID: 24286113 DOI: 10.1111/tri.12221]

50 **Gramm HJ**, Meinhold H, Bickel U, Zimmermann J, von Hammerstein B, Keller F, Dennhardt R, Voigt K. Acute endocrine failure after brain death? *Transplantation* 1992; **54**: 851-857 [PMID: 1332223 DOI: 10.1097/00007890-199211000-00016]

51 **Powner DJ**, Hendrich A, Lagler RG, Ng RH, Madden RL. Hormonal changes in brain dead patients. *Crit Care Med* 1990; **18**: 702-708 [PMID: 2194745 DOI: 10.1097/00003246-199007000-00004]

52 **Masson F**, Thicoïpe M, Latapie MJ, Maurette P. Thyroid function in brain-dead donors. *Transpl Int* 1990; **3**: 226-233 [PMID: 2076172 DOI: 10.1007/BF00366971]

53 **Venkateswaran RV**, Steeds RP, Quinn DW, Nightingale P, Wilson IC, Mascaro JG, Thompson RD, Townend JN, Bonser RS. The haemodynamic effects of adjunctive hormone therapy in potential heart donors: a prospective randomized double-blind factorially designed controlled trial. *Eur Heart J* 2009; **30**: 1771-1780 [PMID: 19324916 DOI: 10.1093/eurheartj/ehp086]

54 **Kutsogiannis DJ**, Pagliarello G, Doig C, Ross H, Shemie SD. Medical management to optimize donor organ potential: review of the literature. *Can J Anaesth* 2006; **53**: 820-830 [PMID: 16873350 DOI: 10.1007/BF03022800]

55 **Novitzky D,** Cooper DK. Results of hormonal therapy in human brain-dead potential organ donors. *Transplant Proc* 1988; **20:** 59-62 [PMID: 3055561]

56 **Rosendale JD**, Kauffman HM, McBride MA, Chabalewski FL, Zaroff JG, Garrity ER, Delmonico FL, Rosengard BR. Hormonal resuscitation yields more transplanted hearts, with improved early function. *Transplantation* 2003; **75**: 1336-1341 [PMID: 12717226 DOI: 10.1097/01.TP.0000062839.58826.6D]

57 **Plurad DS**, Bricker S, Falor A, Neville A, Bongard F, Putnam B. Donor hormone and vasopressor therapy: closing the gap in a transplant organ shortage. *J Trauma Acute Care Surg* 2012; **73**: 689-694 [PMID: 22710780 DOI: 10.1097/TA.0b013e318250b122]

58 **Mangus RS,** Fridell JA, Vianna RM, Milgrom ML, Chestovich P, Vandenboom C, Tector AJ. Severe hypernatremia in deceased liver donors does not impact early transplant outcome. *Transplantation* 2010; 90: 438-443 [PMID: 20679966 DOI: 10.1097/TP.0b013e3181e764c0]

59 **Totsuka E**, Dodson F, Urakami A, Moras N, Ishii T, Lee MC, Gutierrez J, Gerardo M, Molmenti E, Fung JJ. Influence of high donor serum sodium levels on early postoperative graft function in human liver transplantation: effect of correction of donor hypernatremia. *Liver Transpl Surg* 1999; **5**: 421-428 [PMID: 10477844 DOI: 10.1002/Lt.500050510]

60 **Cooper DK**, Novitzky D, Wicomb WN, Basker M, Rosendale JD, Myron Kauffman H. A review of studies relating to thyroid hormone therapy in brain-dead organ donors. *Front Biosci (Landmark Ed)* 2009; **14**: 3750-3770 [PMID: 19273308 DOI: 10.2741/3486]

61 **Zaroff JG**, Rosengard BR, Armstrong WF, Babcock WD, D'Alessandro A, Dec GW, Edwards NM, Higgins RS, Jeevanandum V, Kauffman M, Kirklin JK, Large SR, Marelli D, Peterson TS, Ring WS, Robbins RC, Russell SD, Taylor DO, Van Bakel A, Wallwork J, Young JB. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. *Circulation* 2002; **106**: 836-841 [PMID: 12176957 DOI: 10.1161/01.cir.0000025587.40373.75]

62 **Rosendale JD**, Kauffman HM, McBride MA, Chabalewski FL, Zaroff JG, Garrity ER, Delmonico FL, Rosengard BR. Aggressive pharmacologic donor management results in more transplanted organs. *Transplantation* 2003; **75**: 482-487 [PMID: 12605114 DOI: 10.1097/01.TP.0000045683.85282.93]

63 **Powner DJ**, Hernandez M. A review of thyroid hormone administration during adult donor care. *Prog Transplant* 2005; **15**: 202-207 [PMID: 16252625]

64 **Novitzky D**, Mi Z, Videla LA, Collins JF, Cooper DK. Thyroid hormone therapy and procurement of livers from brain-dead donors. *Endocr Res* 2016; **41**: 270-273 [PMID: 26853445 DOI: 10.3109/07435800.2015.1111902]

65 **Novitzky D**, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. *Transplantation* 2014; **98**: 1119-1127 [PMID: 25405914 DOI: 10.1097/TP.0000000000000187]

66 **Halaris AE**, Belendiuk KT, Freedman DX. Antidepressant drugs affect dopamine uptake. *Biochem Pharmacol* 1975; **24**: 1896-1897 [PMID: 19 DOI: 10.1016/0006-2952(75)90412-8]

67 **Biondi B**, Palmieri EA, Lombardi G, Fazio S. Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. *J Clin Endocrinol Metab* 2002; **87**: 968-974 [PMID: 11889145 DOI: 10.1210/jcem.87.3.8302]

68 **Macdonald PS**, Aneman A, Bhonagiri D, Jones D, O'Callaghan G, Silvester W, Watson A, Dobb G. A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors. *Crit Care Med* 2012; **40**: 1635-1644 [PMID: 22511141 DOI: 10.1097/CCM.0b013e3182416ee7]

69 **Novitzky D**, Mi Z, Collins JF, Cooper DK. Increased Procurement of Thoracic Donor Organs After Thyroid Hormone Therapy. *Semin Thorac Cardiovasc Surg* 2015; **27**: 123-132 [PMID: 26686437 DOI: 10.1053/j.semtcvs.2015.06.012]

70 **Holndonner-Kirst E**, Nagy A, Czobor NR, Fazekas L, Dohan O, Kertai MD, Lex DJ, Sax B, Hartyanszky I, Merkely B, Gal J, Szekely A. The Impact of l-Thyroxine Treatment of Donors and Recipients on Postoperative Outcomes After Heart Transplantation. *J Cardiothorac Vasc Anesth* 2019; **33**: 1629-1635 [PMID: 30467031 DOI: 10.1053/j.jvca.2018.10.024]

71 **Pinsard M**, Ragot S, Mertes PM, Bleichner JP, Zitouni S, Cook F, Pierrot M, Dube L, Menguy E, Lefèvre LM, Escaravage L, Dequin PF, Vignon P, Pichon N. Interest of low-dose hydrocortisone therapy during brain-dead organ donor resuscitation: the CORTICOME study. *Crit Care* 2014; **18**: R158 [PMID: 25056510 DOI: 10.1186/cc13997]

72 **Kotsch K**, Ulrich F, Reutzel-Selke A, Pascher A, Faber W, Warnick P, Hoffman S, Francuski M, Kunert C, Kuecuek O, Schumacher G, Wesslau C, Lun A, Kohler S, Weiss S, Tullius SG, Neuhaus P, Pratschke J. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. *Ann Surg* 2008; **248**: 1042-1050 [PMID: 19092349 DOI: 10.1097/SLA.0b013e318190e70c]

73 **Venkateswaran RV**, Patchell VB, Wilson IC, Mascaro JG, Thompson RD, Quinn DW, Stockley RA, Coote JH, Bonser RS. Early donor management increases the retrieval rate of lungs for transplantation. *Ann Thorac Surg* 2008; **85**: 278-86; discussion 286 [PMID: 18154823 DOI: 10.1016/j.athoracsur.2007.07.092]

74 **Venkateswaran RV**, Dronavalli V, Lambert PA, Steeds RP, Wilson IC, Thompson RD, Mascaro JG, Bonser RS. The proinflammatory environment in potential heart and lung donors: prevalence and impact of donor management and hormonal therapy. *Transplantation* 2009; **88**: 582-588 [PMID: 19696643 DOI: 10.1097/TP.0b013e3181b11e5d]

75 **Dhar R**, Cotton C, Coleman J, Brockmeier D, Kappel D, Marklin G, Wright R. Comparison of high- and low-dose corticosteroid regimens for organ donor management. *J Crit Care* 2013; **28**: 111.e1-111.e7 [PMID: 22762934 DOI: 10.1016/j.jcrc.2012.04.015]

76 **Meyfroidt G**, Gunst J, Martin-Loeches I, Smith M, Robba C, Taccone FS, Citerio G. Management of the brain-dead donor in the ICU: general and specific therapy to improve transplantable organ quality. *Intensive Care Med* 2019; **45**: 343-353 [PMID: 30741327 DOI: 10.1007/s00134-019-05551-y]

77 **Kramer AH**, Baht R, Doig CJ. Time trends in organ donation after neurologic determination of death: a cohort study. *CMAJ Open* 2017; **5**: E19-E27 [PMID: 28401114 DOI: 10.9778/cmajo.20160093]

78 **Singh JN**, Nguyen T, Kerndt CC, Dhamoon AS. Physiology, Blood Pressure Age Related Changes. 2021 Jul 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan- [PMID: 30725982]

**Footnotes**

**Conflict-of-interest statement:** No conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** March 20, 2021

**First decision:** July 18, 2021

**Article in press:**

**Specialty type:** Transplantation

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Gomes A **S-Editor:** Fan JR **L-Editor: P-Editor:**

**Table 1 Donor management goals**

|  |  |
| --- | --- |
| **Goals** | **Monitoring** |
| MAP ≥ 65 mmHg | Invasive arterial pressure |
| CVP ≥ 10 | Central venous catheter |
| Hemoglobin ≥ 10 g/dL | Blood gas analysis |
| Diuresis ≥ 1 mL/kg/h |
| Na 135-155 meq/L |

MAP: Mean arterial pressure; CVP: Central venous pressure.

**Table 2 Vasoactive drugs and hormonal therapy in brain death donors–proposed regimen**

|  |  |  |
| --- | --- | --- |
|  | **Dosage** | **Comments** |
| **Vasoactive** |  |  |
| Norepinephrine (mcg/kg/min) | ≤ 0.2 mcg/kg/min, if higher dosage needed add vasopressin | In potential heart donors, the lowest dosage is preferable |
| Vasopressin (U/h) | Up to 2.5 U/h |  |
| **Hormonal replacement therapy** |  |  |
| Idrocorticosteroid | 100 mg bolus, 200 mg/24 h infusion |  |
| T3 | 4 mcg intravenous bolus, followed by infusion of 3 mcg *per* hour | T3 could be preferred since it is immediately available to tissues |
| Desmopressin (DDVAP) | 4 mcg intravenous bolus eventually repeat every 6 to 8 h as needed |  |

DDVAP: 1-deamino-8-D-arginine vasopressin.